Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

ICPO Theranostics Virtual Summit 2024: Advancing a New Era in Precision Oncology

NextEdge Admin

27 Nov 2024

2 min 44 sec

Virtual Summit,Precision Oncology,Radiopharmaceuticals

The ICPO Theranostics Virtual Summit 2024, hosted by the International Centers for Precision Oncology Foundation (ICPO) on November 14–15, 2024, focused on “A New Era of Alpha Emitters and Radiopharmaceuticals.” Live-streamed from Munich, the event drew over 400 participants from 37 countries, featuring 35 experts discussing innovations such as FAP, CA9, CXCR4, and GPC3, which hold transformative promise for treating therapy-resistant malignancies.

Udo J. Vetter, Chairman of the ICPO Board of Trustees, opened the Summit by highlighting ICPO’s achievements and commending the efforts of Summit Chairs Prof. Frederik L. Giesel and Prof. Richard P. Baum, along with CEO Odile Jaume, for curating a world-class program. He also recognized the collaboration with the Scientific Advisory Board, comprising global luminaries such as Cathy S. Cutler (USA), Cristina Müller (Switzerland), and Ken Herrmann (Germany).

The Summit began with a keynote by Prof. Steven M. Larson, emeritus member of Memorial Sloan Kettering Cancer Center, presenting the “History of Alpha Therapy.” On day two, Prof. Andrew M. Scott, Director at Australia’s Olivia Newton-John Cancer Research Institute, shared groundbreaking insights into FAP-targeted theranostics in oncology and fibrosis with his talk “History of FAP Till Today.”

Summit Chair Prof. Giesel emphasized the importance of this platform in advancing research and clinical practice, while Co-Chair Prof. Baum praised the cutting-edge innovations presented, calling the event a milestone for cancer patients worldwide. CEO Odile Jaume expressed gratitude to speakers, sponsors, and participants for elevating the Summit’s standard and strengthening ICPO’s mission to empower the global theranostics community.

This collaborative event showcased state-of-the-art advancements, fostering international exchange and shaping the future of precision oncology.